Clinical Trial Update: HAIC Plus A+T for Patients With High-risk HCC: a Single-arm Phase 2 Trial [Phase 2]

View source ↗

Summary

A single-arm Phase 2 trial evaluating HAIC plus A+T in high-risk hepatocellular carcinoma is being conducted, with unclear status.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• HAIC plus A+T

Snippet

Sponsor: Sun Yat-sen University | Conditions: Hepatocellular Carcinoma | Phase 2 | Status: UNKNOWN